RESUMO
AIM OF THE STUDY: We reported the association between interleukin 8 (IL-8) polymorphisms (-251T/A and +781C/T) and hepatocellular carcinoma (HCC) risk in a meta-analysis. MATERIAL AND METHODS: Scopus, PubMed, Web of Science, and Cochrane Library databases were searched until 21 November 2020. The analyses were performed by RevMan 5.3 software using odds ratios (ORs) and 95% confidence intervals (CIs). Also, the analysis of publication bias was performed by CMA 2.0 software. RESULTS: Searching databases/sources, five articles including ten studies were entered into the meta-analysis. The pooled ORs for -251T/A polymorphism were 1.07 (p = 0.55), 1.04 (p = 0.75), 1.31 (p = 0.24), 1.24 (p = 0.31), and 1.85 (p = 0.29) for allele, homozygote, heterozygote, recessive and dominant models, respectively. With regards to +781C/T polymorphism, the pooled ORs were 0.74 (p = 0.07), 0.53 (p = 0.03), 0.83 (p = 0.41), 0.75 (p = 0.19), and 0.57 (p = 0.02) for allele, homozygote, heterozygote, recessive, and dominant models, respectively. CONCLUSIONS: The findings of the meta-analysis showed a lack of significant association between IL-8 (-251T/A) polymorphism and the HCC risk, whereas the TT genotype of IL-8 (+781C/T) polymorphism had a protective role in HCC.
RESUMO
AIM OF THE STUDY: We reported the association between interleukin 6 polymorphisms (rs1800796, rs1800795, rs2069837, rs17147230, and rs1800797) and hepatocellular carcinoma (HCC) susceptibility in a meta-analysis. MATERIAL AND METHODS: The studies were retrieved by searching the search terms in Scopus, PubMed, Web of Science, and Cochrane Library databases until June 2020. The analyses were done by RevMan 5.3 software using odds ratios (ORs) and 95% confidence intervals (CIs) and the analysis of publication bias and sensitivity analyses were performed by CMA 2.0 software. RESULTS: Searching through the databases, 316 records were retrieved and finally 13 studies were analyzed in the present meta-analysis. For the rs1800797 polymorphism, there was an elevated risk of AA genotype (OR = 2.68, p = 0.03) in HCC patients compared to healthy controls. Also, there was an elevated risk of AA (OR = 3.06, p = 0.04) and GA (OR = 2.61, p = 0.005) genotypes in HCC patients compared to liver cirrhosis patients. For rs2069837 polymorphism, there was an elevated risk of GG genotype (OR = 2.25, p = 0.01) in HCC patients compared to healthy controls. For rs17147230, T allele (OR = 1.31, p = 0.03) and TT genotype (OR = 1.83, p = 0.02) had elevated risks in HCC patients compared to healthy controls. CONCLUSIONS: The present meta-analysis confirmed that there was an elevated risk of the AA and GA genotypes of rs1800797 polymorphism and the GG genotype of rs2069837, and the T allele and TT genotype of rs17147230 in HCC.